Begoña Jiménez - Concepedia

Author

Begoña Jiménez

Hospital Clínico Universitario Virgen de la Victoria

Also Known As

B Jimenez, B Jiménez, B. Jimenez, B. Jiménez, Begona Jimenez, Begona Jiménez, Begoña Jimenez, Begoña Jiménez, Britany Jiménez

Publications

823

Citations

H-Index

Concepts

All Affiliations

Hospital Clínico Universitario Virgen de la Victoria Universidad de Málaga Instituto de Investigación Biomédica de Málaga Institut Català d'Oncologia Institute of Cancer Research

About

Begoña Jiménez is an author at Hospital Clínico Universitario Virgen de la Victoria specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	207
2	Health Sciences	3	3	77
3	Pathology	3	3	72
4	Engineering	1	1	23
5	Health Informatics	1	1	23

Begoña Jiménez

Publications

646

Citations

H-Index

Page 1

	Year	Citations
Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index Nuria Ribelles, Lidia Pérez-Villa, José M. Jerez, Breast Cancer Research	2013	116
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay Aleix Prat, Patricia Galván, Begoña Jiménez, Clinical Cancer Research	2015	95
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study Manuel Ruíz‐Borrego, Begoña Jiménez, Silvia Antolín, Investigational New Drugs Phase Ib StudyOncologyMedicineCancer Cell BiologyBreast Cancer	2018	54
Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients Begoña Jiménez, José Trigo, Bella Pajares, Oral Oncology OncologyNeck Cancer PatientsCancer ManagementPharmacologyWeekly Paclitaxel	2012	47
A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse Aleix Prat, Aňa Lluch, Arran Turnbull, Clinical Cancer Research	2016	44
Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status Alfonso Sánchez‐Muñoz, Elísabeth Pérez-Ruiz, M.I. Sáez, Clinical & Translational Oncology Palliative CareCancer ManagementAdvanced Solid TumoursLimited ImpactCancer Treatment	2011	43
Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study Sofía Ruiz-Medina, S Justo Gil, Begoña Jiménez, Cancers	2021	36
Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials Saeed Rafii, Desamparados Roda, Elena Geuna, Clinical Cancer Research	2015	35
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies Teresa Morán, Jia Wei, Manuel Cobo, Annals of Oncology OncologyMedicinePathologyBrca1-rap80 Expression CustomizationBiomarker-directed Randomized Trials	2014	30
Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials Elena Geuna, Desamparados Roda, Saeed Rafii, British Journal of Cancer	2015	29

Page 1